Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
Lisata Therapeutics, Inc. (LSTA)
Company Research
Source: GlobeNewswire
Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat diseases Catalent’s preclinical study results provide proof-of-concept support for leveraging certepetide-related biology through its use as an ADC payload BASKING RIDGE, N.J. and TAMPA, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, today announced a global product license agreement that allows Catalent to incorporate Lisata’s certepetide into antibody-drug conjugates (“ADCs”) developed using Catalent’s SMARTag® technology platform. Certepetide, a proprietary, internalizing RGD (arginyl-glycyl-aspa
Show less
Read more
Impact Snapshot
Event Time:
LSTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LSTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LSTA alerts
High impacting Lisata Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LSTA
News
- Lisata Therapeutics (NASDAQ:LSTA) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Lisata (LSTA) Q3 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ... [Yahoo! Finance]Yahoo! Finance
- Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’GlobeNewswire
LSTA
Earnings
- 11/6/25 - Beat
LSTA
Sec Filings
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- 10/14/25 - Form 8-K
- LSTA's page on the SEC website